Broad Institute

NOVEMBER 6, 2024

By Leah Eisenstadt November 6, 2024 Credit: Ricardo Job-Reese, Broad Communications Despite being one of the rarer complications from immune checkpoint inhibitors, myocarditis is the most deadly. Our results provide a more detailed picture of what’s happening in the heart and suggest intriguing new ways forward to improve patient care.”

Immune Response 118

Immune Response Medical Schools Clinical Trials Treatment 118

The Pharma Data

JULY 15, 2021

Antibody and T-cell immune responses strong and stable at eight months after immunization Demonstrated neutralizing antibody activity against the Delta variant (B.1.617.2) variants, as well as the original SARS-CoV-2 strain (WA1/2020). and other SARS-CoV-2 variants of concern , including the Alpha (B.1.1.7),

Immune Response 52

Immune Response Vaccine Clinical Trials FDA 52

The Pharma Data

NOVEMBER 3, 2020

Deucravacitinib works by inhibiting the tyrosine kinase 2 (TYK2) enzyme, which is linked to an immune response that causes skin inflammation. The company is investigating deucravacitinib for a wide range of autoimmune diseases. The drug reduced the severity of psoriasis by 75 percent in patients vs. placebo.

Immune Response 52

Immune Response Drugs Trials Disease 52

The Pharma Data

DECEMBER 29, 2020

Experts believe brain-related effects may be tied to the body’s immune response to the virus and possibly to vascular problems or surges of inflammation caused by the disease. ” © 2020 HealthDay. Posted: December 2020. Most patients have been in their 30s, 40s and 50s. All rights reserved.

Virus 52

Virus Hospitals Immune Response Doctors 52

The Pharma Data

DECEMBER 31, 2020

Monthly News Roundup – December 2020. In studies, the vaccines were found to be 94% to 95% effective in preventing COVID-19 disease. The vaccine teaches the cells to make a piece of the spike protein, which triggers an immune response to help prevent illness if later exposed to the virus. In December, the U.S.

FDA Approval 52

FDA Approval Vaccine FDA Treatment 52

Drug Target Review

JANUARY 15, 2024

Chronic obstructive pulmonary disease Chronic obstructive pulmonary disease (COPD) is the third leading cause of global deaths. The pathogenesis of COPD is based on the innate and adaptive inflammatory immune response to the inhalation of toxic particles and gases. The Pathology of Chronic Obstructive Pulmonary Disease.

Immune Response 113

Immune Response Disease Science Therapies 113

Broad Institute

NOVEMBER 6, 2024

Alexandra-Chloé Villani: The problem is growing as more patients undergo ICI treatment each year, with more than 230,000 patients in the US treated with ICIs in 2020. That gives us a lot of hope, because we can think about targeting the inflamed organ that is failing without halting the immune response to the tumor.

Research 124

Research Immune Response Hospitals Therapies 124

The Pharma Data

NOVEMBER 18, 2020

19, 2020 /PRNewswire/ — OBI Pharma, Inc. “Based upon our anti-Globo H targeted approaches in cancers of high unmet needs, OBI Pharma is proud to have presentations on the progress of our trial presented at ESMO-Asia 2020 for our novel therapeutic cancer vaccine, OBI-833.” TAIPEI, Taiwan , Nov. About OBI Pharma.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

DECEMBER 31, 2020

31, 2020 — Blood vessel damage and inflammation in the brains of deceased COVID-19 patients suggest the damage is not caused by the virus, but the body’s immune response to it. The spots were surrounded by T cells — signs of an immune response. © 2020 HealthDay. . © 2020 HealthDay.

Immune Response 52

Immune Response Virus Doctors Research 52

The Pharma Data

DECEMBER 15, 2020

A healthy immune system defends the body against disease and other conditions. However, if the immune system malfunctions, it can attack healthy cells, tissues and organs. Autoimmune disease impacts different parts of the body, weakening functionality. Autoimmune diseases affect more than 24 million people in the U.S.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

The Pharma Data

JANUARY 25, 2021

In a surprise move, Merck announced that it is giving up on its two coronavirus vaccine candidates after seeing a subpar immune response and shifting its focus to a pair of investigational coronavirus treatments. MK-7110, previously known as CD24Fc, is a recombinant fusion protein that controls the body’s inflammatory response.

Vaccine 52

Vaccine Immune Response Trials Clinical Trials 52

The Pharma Data

DECEMBER 8, 2020

8, 2020 — AstraZeneca’s COVID-19 vaccine is safe and effective, new data from late-stage trials shows. Overall, the vaccine protected against symptomatic disease in 70% of cases, according to a team led by researchers from Oxford University in England. © 2020 HealthDay. Posted: December 2020. TUESDAY, Dec.

Vaccine 52

Vaccine Trials Immune Response RNA 52

The Pharma Data

DECEMBER 16, 2020

16, 2020 (GLOBE NEWSWIRE) — Novavax , Inc. Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an Advance Purchase Agreement with the government of New Zealand for the purchase of 10.7 GAITHERSBURG, Md., About Novavax. Novavax, Inc.?(Nasdaq:

Vaccine 52

Vaccine Government Immune Response Clinical Trials 52

The Pharma Data

JUNE 25, 2021

Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% 100) against moderate or severe disease. It was generally well-tolerated and elicited robust antibody response in Phase 1/2 clinical testing.

Vaccine 40

Vaccine Trials Disease Immune Response 40

The Pharma Data

JUNE 26, 2021

We believe that mRNA technology could have several advantages for a seasonal flu application including the potential ability to demonstrate robust immune responses based on preclinical data to date, enable antigen specificity within a short timeframe from seasonal virus strain selection, and deploy agile manufacturing capacity.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

MARCH 13, 2022

That’s because the mutations that led to the variant’s emergence aren’t found in the regions of the virus that stimulates one type of cellular immune response, says an international research team from Johns Hopkins Medicine, in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and ImmunoScape, a U.S.-Singapore

Virus 52

Virus Immune Response Vaccine Research 52

The Pharma Data

JUNE 25, 2021

In the unprecedented context of at least 13 variants circulating within the study population subset assessed at this interim analysis, CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity and did not meet prespecified statistical success criteria. About CureVac.

Vaccine 52

Vaccine Trials Immune Response Virus 52

NIH Director's Blog: Drug Development

JUNE 30, 2020

It’s now clear that nearly everyone who recovers from coronavirus disease 2019 (COVID-19) produces antibodies that specifically target SARS-CoV-2, the novel coronavirus that causes the infection. But there is a catch: 99 percent of the study’s participants didn’t make enough neutralizing antibodies to mount an ideal immune response.

Immune Response 52

Immune Response Virus Vaccine Research 52

PLOS: DNA Science

MAY 16, 2024

These factors are converging to enable both identification of novel infectious diseases as well as microbial resistance, before these threats can impact public health, write a team from the European Society for Clinical Microbiology and Infectious Diseases in Frontiers in Science. COVID clearly caught us off guard.

Virus 98

Virus DNA RNA Laboratories 98

The Pharma Data

NOVEMBER 18, 2020

18, 2020 — Children should be included in clinical trials for a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine at the earliest stages, according to a letter from the president of the American Academy of Pediatrics (AAP), on behalf of more than 67,000 pediatricians and pediatric medical and surgical subspecialists. .”

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. the vaccines global business unit of Sanofi, to develop mRNA vaccines for up to five infectious disease pathogens. Expected to enroll 415 participants; interim results expected in Q3 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

Creative Biolabs

JULY 12, 2020

Professor Florian Klein, the paper’s corresponding author, explained, “our goal is to better understand the immune response to SARS-CoV-2 and to identify highly potent antibodies that can be used to prevent and treat COVID-19.” They are expected to enter clinical development later this year.

Immune Response 52

Immune Response Laboratories Clinical Trials Clinical Development 52

The Pharma Data

DECEMBER 3, 2020

4, 2020 08:00 UTC. Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant. A global Phase 2/3 efficacy study of the S-Trimer vaccine candidate in combination with GSK’s pandemic adjuvant system is expected to begin in December 2020. CHENGDU, China.–(

Vaccine 52

Vaccine Immune Response Virus RNA 52

The Pharma Data

DECEMBER 11, 2020

11, 2020 — More than 15 million Americans have been infected by the COVID-19 virus, and many may be questioning whether they need to receive one of the two coronavirus vaccines now on the verge of approval from U.S. William Schaffner, a professor of infectious diseases at Vanderbilt University Medical Center in Nashville, Tenn.

Vaccine 52

Vaccine Immune Response Virus Trials 52

The Pharma Data

NOVEMBER 10, 2020

. P otential to be a safer and effective alternative to the intravenous immunotherapies currently used for Crohn’s Disease. Crohn’s Disease Therapeutics Market Size $4.7 Oral and nasal administration routes are both physiologic approaches to stimulate the mucosal immune system to induce disease modifying benefits.”.

Clinical Trials 40

Clinical Trials Science Disease Trials 40

The Pharma Data

APRIL 22, 2023

Multiple sclerosis (MS) is a devastating autoimmune disease that destroys the protective myelin covering around nerves, disrupting communication between the brain and body, and causing patients’ ability to move and function to progressively decline. million individuals that currently have to live with the disease.

Therapies 40

Therapies Immune Response Small Molecule Engineering 40

The Pharma Data

JUNE 30, 2021

Yasmin Parr’s study of FeLV shows that the outcome of FeLV infection is influenced by the host immune response, with progressively infected cats, so cats whose conditions are worsening, having weaker immune responses. “In References. For more information, please visit www.abcdcatsvets.org.

Immune Response 52

Immune Response Virus Disease Doctors 52

The Pharma Data

JULY 8, 2021

In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. In addition, we observe a persistent and particularly robust, durable cellular immune response,” said Mathai Mammen, M.D., 2) variants during the study period.

Vaccine 52

Vaccine Immune Response Pharmaceutical Companies Disease 52

The Pharma Data

NOVEMBER 22, 2020

23, 2020 10:10 UTC. The partnership will harness both FJB and IONTAS’ proprietary antibody libraries and technology platforms to investigate novel therapeutic targets for autoimmune and inflammatory diseases. PORTO, Portugal & CAMBRIDGE, England & LONDON–( BUSINESS WIRE )– FairJourney Biologics S.A (FJB)

Immune Response 52

Immune Response Engineering Clinical Research Disease 52

The Pharma Data

SEPTEMBER 8, 2021

While these results are disappointing, w e believe th e rilzabrutinib clinical program holds great potential to address the unmet treatment needs of people living with immune-mediated diseases , ” said Naimish Patel, Head of Global Development, Immunology and Inflammation. “ 2020 Apr 9;72(9):1435–46. doi: 10.1002/art.41275.

Immune Response 52

Immune Response Trials Treatment Disease 52

The Pharma Data

JUNE 26, 2021

BioNTech SE (NASDAQ: BNTX, “BioNTech” or “the Company”), announced that the first patient has been treated in its BNT111 Phase 2 cancer vaccine trial (2020-002195-12; NCT04526899). “Our vision is to harness the power of the immune system against cancer and infectious diseases. About BioNTech.

Clinical Trials 52

Clinical Trials Trials Immune Response Vaccine 52

The Pharma Data

JANUARY 22, 2021

24, 2020 ). The EUA covers adults and children over age 12 who have mild or moderate COVID-19 and are at high risk for severe disease.

Immune Response 52

Immune Response Clinical Trials Hospitals Trials 52

The Pharma Data

DECEMBER 22, 2020

22, 2020 — In very rare cases, some people have had severe allergic reactions after receiving the new COVID-19 vaccines, leading the American College of Allergy , Asthma, and Immunology (ACAAI) to issue updated guidance for Americans with allergies. © 2020 HealthDay. Posted: December 2020. TUESDAY, Dec. Source link.

Vaccine 52

Vaccine Immune Response Treatment Disease 52

Drug Target Review

OCTOBER 26, 2023

1 Adeno-associated virus (AAV) vectors are the leading platform for in vivo gene delivery for the treatment of various human diseases. 9 In addition, host immune responses further add to the complexity of developing cell-specific AAV capsids for clinical applications. Nature 578 , 229-236 (2020). References Doudna JA.

Engineering 105

Engineering Virus Therapies Immune Response 105

Drug Target Review

OCTOBER 4, 2023

Antibody-drug conjugates (ADCs) have been a groundbreaking approach to cancer treatment with their ability to deliver cytotoxic drugs directly to diseased cells while sparing healthy tissues. 15 ISACs use small immuno-agonist molecules conjugated to the antibody to boost the immune response while minimising toxicity.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

The Pharma Data

FEBRUARY 22, 2021

New Phase 2 study assesses potential for refined antigen formulation to achieve optimal immune response, including in older adults. Sanofi and GSK’s adjuvanted recombinant protein-based COVID-19 vaccine candidate was selected in July 2020 by the U.S. In parallel, development work on new SARS-CoV-2 variants underway.

Vaccine 52

Vaccine Immune Response Trials Clinical Trials 52

The Pharma Data

DECEMBER 13, 2020

14, 2020 /PRNewswire/ — Synlogic, Inc. SYNB1891 is an investigational drug for the intra-tumoral treatment of solid tumors and lymphoma, composed of an engineered Synthetic Biotic designed to activate the STING pathway in the tumor microenvironment in order to upregulate the patient’s immune response.

Immune Response 40

Immune Response Treatment Engineering Clinical Trials 40